Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution - Top-Institutions - MDSpire

Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution

  • By

  • Renee Morecroft

  • Jordan Phillipps

  • Amrat Kumar

  • Jacob Strelnikov

  • George Nassief

  • Naganathan Mani

  • Jennifer Gould

  • Tanner Johanns

  • George Ansstas

  • April 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Ophthalmic Oncology
    • Medical Oncology
    • Interventional Radiology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Ophthalmic Oncology
    • Hepatic Oncology
    • Interventional Radiology

  • #3

    Wills Eye Hospital / Thomas Jefferson University
    Wills Eye Hospital / Thomas Jefferson University

    Philadelphia, PA

    Key Differentiators

    • Ophthalmic Oncology
    • Medical Oncology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Ophthalmic Oncology
    • Interventional Radiology
    • Medical Oncology

Original Source(s)

Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution

  • by Renee Morecroft, Jordan Phillipps, Amrat Kumar, Jacob Strelnikov, George Nassief, Naganathan Mani, Jennifer Gould, Tanner Johanns, George Ansstas

  • April 23, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”